As any biotech investor will tell you freely, investing in biopharma is rife with risks. Clinical trials can miss the mark, and successful medicines on the market can get outcompeted by newer entrants. 

But there are a few biopharma companies that offer scrumptious rewards for shareholders, and without a high chance of catastrophic failure along the way. To do that, they tend to have a mix of reliable sales alongside a bunch of ambitious projects to provide upside.

Let's take a look at a trio of those businesses right now to see if you might be interested in using them as wealth-building investments.

Continue reading

Source Fool.com